Vaccination programme, population size, proportion of invasive pneumococcal disease (IPD) cases serotyped and number of IPD cases per year among older adults aged ≥65 years by site: SpIDnet/I-MOVE+ multicentre study
| Sites | Vaccine used (uptake) in 2015 | Population aged ≥65 years | % typed cases†† | Adjusted number of cases* per year | |||||||
| In infants | In elderly (any) | 2015 | 2015 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | |
| CZ | U, PCV10/PCV13 (71%)† | PPV23 (NA) | 1 932 412 | 93% | 151 | 139 | 134 | 142 | 183 | 157 | 191 |
| DK | U, PCV13 (94%) | PPV23 (11%), PCV13 (3%) | 1 072 422 | 94% | 569 | 539 | 540 | 544 | 475 | 483 | 560 |
| EW | U, PCV13 (94%) | PPV23 (70%) | 11 000 000 | 96% | 2380 | 2378 | 2158 | 2189 | 2138 | 2187 | 2739 |
| FI | U, PCV10 (94%) | Risk groups (PPV23 <5%) | 1 123 103 | 99% | 295 | 304 | 297 | 342 | 319 | 355 | 427 |
| FR | U, PCV13 (94%) | Risk groups (PPV23 8%) | 9 209 601 | NA‡ | 2539 | 2410 | 2396 | 2258 | 1881 | 1640 | 1820 |
| IE | U, PCV13 (93%) | PPV23 (36%)§; PCV13 risk groups¶ | 606 011 | 88% | 156 | 147 | 160 | 177 | 171 | 168 | 189 |
| NL | U, PCV10 (94%) | Risk groups | 751 921 | 100% | 331 | 303 | 334 | 360 | 377 | 313 | 402 |
| NO | U, PCV13 (93%) | PPV23 (15%) | 834 302 | 99% | 381 | 390 | 381 | 327 | 307 | 311 | 312 |
| SC | U, PCV13 (97%) | PPV23 (69%) | 982 998 | 89% | 219 | 255 | 218 | 238 | 285 | 221 | 313 |
| SE | U, PCV10/PCV13 (97%)† | Risk groups | 1 912 884 | 95% | 866 | 819 | 743 | 832 | 789 | 747 | 787 |
| CAT | PCV10/PCV13 (78%) | PPV23 (60%) | 1 361 617 | 90% | 490 | 456 | 344 | 413 | 451 | 388 | 449 |
| MAD | PCV10/PCV13 (77%)§ | PPV23 (60%) | 1 079 912 | 91% | 192 | 174 | 184 | 190 | 183 | 238 | 254 |
| NAV | (PCV10) PCV13 (81%)** | PPV23 (57%) | 121 236 | 90% | 30 | 22 | 33 | 34 | 26 | 25 | 30 |
| All | NR | NR | 31 988 419 | 95% | 8599 | 8336 | 7922 | 8046 | 7585 | 7233 | 8473 |
*Adjusted for the sensitivity of the surveillance system.
†PCV10 and PCV13 are used in similar proportions in those sites.
‡Not computed as two different datasets are used (no case reconciliation).
§2013.
¶ Starting August 2015.
**PCV13 was used almost exclusively as the PCV10 uptake in children aged <2 years has been <1% since 2012.
††The number of serotyped cases divided by all reported cases in that site in 2015.
CAT, Catalonia; CZ, Czech Republic; DK, Denmark; EW, England & Wales; FI, Finland; FR, France; IE, Ireland; MAD, Madrid; NAV, Navarra; NL, the Netherlands; NOR, Norway; NA, not available; NR, not relevant; SC, Scotland; SE, Sweden; U, universal programme.